Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Investment analysts at Wedbush increased their Q3 2025 EPS estimates for shares of Fennec Pharmaceuticals in a report issued on Sunday, December 22nd. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn $0.56 per share for the quarter, up from their previous forecast of $0.46. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' FY2026 earnings at $3.03 EPS and FY2027 earnings at $4.06 EPS.
Separately, Stephens upgraded Fennec Pharmaceuticals to a "strong-buy" rating in a report on Monday, November 18th.
View Our Latest Report on Fennec Pharmaceuticals
Fennec Pharmaceuticals Trading Up 0.2 %
TSE:FRX traded up C$0.02 during trading hours on Tuesday, reaching C$8.93. 100 shares of the company were exchanged, compared to its average volume of 2,011. Fennec Pharmaceuticals has a 52-week low of C$5.65 and a 52-week high of C$15.43. The stock has a 50 day simple moving average of C$7.19 and a 200 day simple moving average of C$7.67. The firm has a market cap of C$244.32 million, a price-to-earnings ratio of 89.30 and a beta of 0.25. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17.
Insider Transactions at Fennec Pharmaceuticals
In related news, Senior Officer Robert Christopher Andrade purchased 15,816 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average cost of C$3.43 per share, for a total transaction of C$54,248.88. Also, Director Rostislav Christov Raykov acquired 25,000 shares of the business's stock in a transaction on Friday, December 20th. The stock was bought at an average cost of C$3.87 per share, for a total transaction of C$96,840.00. Insiders have bought a total of 41,612 shares of company stock worth $157,868 in the last three months. 16.20% of the stock is currently owned by company insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
